Embryonic stem cell-specific signature in cervical cancer

Tumor Biology

Volumn 35, Issue 3, 2014, Pages 1727-1738

  Organista Nava, Jorge ^a,b   Gómez Gómez, Yazmín ^a,b   Gariglio, Patricio ^b  

^a INSTITUTO DE FISIOLOGÍA CELULAR   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

Cancer stem cells; Cervical cancer; ES cell markers in cervical cancer cells; Human papillomavirus; Squamous cell carcinoma; Transcription factors

Indexed keywords

CELL ADHESION; CELL GROWTH; CELL MIGRATION; CELL SPECIFICITY; CELL SURVIVAL; CELL TRANSFORMATION; COLONY FORMATION; EMBRYONIC STEM CELL; HUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; TUMOR DIFFERENTIATION; TUMOR INVASION; UTERINE CERVIX CANCER; UTERINE CERVIX EPITHELIUM; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CELL TRANSFORMATION, NEOPLASTIC; EMBRYONIC STEM CELLS; FEMALE; HUMANS; TRANSCRIPTOME; UTERINE CERVICAL NEOPLASMS;

EID: 84899087600     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1321-y     Document Type: Review

References (162)

1. Wang X, Liu R, Ma B, Yang K, Tian J, Jiang L, Bai ZG, Hao XY, Wang J, Li J. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev 2010;CD007563.
2. Hakim A, Lin P, Wilczynski S, Nguyen K, Lynes B, Wakabayashi M. Indications and efficacy of the human papillomavirus vaccine. Curr Treat Options in Oncol. 2010;8:393-401.
3. IARC GSmfMNiwefenmfbm, using a set of age-, sex and site-specific incidence mortality ratios obtained by the aggregation of recorded cancer registry data from Cuba, Costa Rica and Puerto Rico. For further details refer to http://globocan.iarc.fr/DataSource-and-methods.asp and http://globocan.iarc. fr/method/method.asp?country=484) [Accesed September 15, 2010].
4. Eltahir HA, Elhassan AM, Ibrahim ME. Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer. Mole Med Rep. 2012;6:473-6.
5. Manavi M, Hudelist G, Fink-Retter A, Gschwandtler-Kaulich D, Pischinger K, Czerwenka K. Gene profiling in pap-cell smears of high-risk human papillomavirus-positive squamous cervical carcinoma. Gynecol Oncol. 2007;105:418-26.
6. Acevedo-Rocha CG, Munguía-Moreno JA, Ocádiz-Delgado R, Gariglio P. A transcriptome- and marker-based systemic analysis of cervical cancer. In Intech (ed) Topics on cervical cancer with an advocacy for prevention. Croacia, 2012, pp. 155-196.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-11.
8. Lobo NA, Shimono Y, Qian D, Clarke MF. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007;23:675-99.
9. Stingl J, Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007;7:791-9.
10. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-72.
11. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-20.
12. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature. 2004;432:324-31.
13. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40:499-507.
14. Assou S, Le Carrour T, Tondeur S, Ström S, Gabelle A, Marty S, et al. A meta analysis of human embryonic stem cells transcriptome integrated into a web based expression atlas. Stem Cells. 2007;25:961-73.
15. Boyer LA, Lee TI, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell. 2005;122:947-56.
16. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulators by polycomb in human embryonic stem cells. Cell. 2006;125:301-13.
17. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-myc protein. Genes Dev. 2003;17:1115-29.
18. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-myc in Burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 2003;100:8164-9.
19. Shrihari TG. Cancer stem cells - therapeutic boon. J Cancer Sci Ther. 2011;3:197-200.
20. Liu S, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res. 2005;7:86-95.
21. Shenghui H, Nakada D, Morrison SJ. Mechanisms of stem cell self-renewal. Annu Rev Cell Dev Biol. 2009;25:377-406.
22. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 2003;3:895-902.
23. Marx J. Mutant stem cells may seed cancer. Science. 2003;301:1308-10.
24. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.
25. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci U S A. 2006;103:11154-9.
26. Friel AM, Sergent PA, Patnaude C, Szotek PP, Oliva E, Scadden DT, et al. Functional analyses of the cancer stem cell-like properties of human endometrial tumor initiating cells. Cell Cycle. 2008;7:242-9.
27. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946-51.
28. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396-401.
29. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827-33.
30. Zhang S-L, Wang Y-S, Zhou T, Yu X-W, Wei Z-T, Li Y-L. Isolation and characterization of cancer stem cells from cervical cancer hela cells. Cytotechnology. 2012;64:477-84.
31. Feng D, Peng C, Li C, Zhou Y, Li M, Ling B, et al. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol Rep. 2009;22:1129-34.
32. Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, et al. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci U S A. 2012;109:10516-21.
33. López J, Ruíz G, Organista-Nava J, Gariglio P, García-Carrancá A. Human papillomavirus infections and cancer stem cells of tumors from the uterine cervix. Open Virol J. 2012;6:232-40.
34. Herfs M, Vargas S, Yamamoto Y, Howitt B, Nucci M, Hornick J, et al. A novel blueprint for «top down» differentiation defines the cervical squamocolumnar junction during development, reproductive life and neoplasia. J Pathol. 2013;229:460-8.
35. Martens JE, Arends J, Van Der Linden PJQ, De Boer BAG, Helmerhorst TJM. Cytokeratin 17 and p63 are markers of the HPV target cell, the cervical stem cell. Anticancer Res. 2004;24:771-6.
36. Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirie F, Rigby PWJ, et al. A pou-domain transcription factor in early stem cells and germ cells of the mammalian embryo. Nature. 1990;345:686-92.
37. Okamoto K, Okazawa H, Okuda A, Sakai M, Muramatsu M, Hamada H. A novel octamer binding transcription factor is differentially expressed in mouse embryonic cells. Cell. 1990;60:461-72.
38. Liu D, Zhou P, Zhang L, Wu G, Zheng Y, He F. Differential expression of Oct4 in HPV-positive and HPV-negative cervical cancer cells is not regulated by DNA methyltransferase 3A. Tumour Biol. 2011;32:941-50.
39. Pereira L, Yi F, Merrill BJ. Repression of nanog gene transcription by Tcf3 limits embryonic stem cell self-renewal. Mol Cell Biol. 2006;26:7479-91.
40. Pan G, Thomson JA. Nanog and transcriptional networks in embryonic stem cell pluripotency. Cell Res. 2007;17:42-9.
41. Ezeh UI, Turek PJ, Reijo RA, Clark AT. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer. 2005;104:2255-65.
42. Saiki Y, Ishimaru S, Mimori K, Takatsuno Y, Nagahara M, Ishii H, et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol. 2009;16:2638-44.
43. Chiou S-H, Yu C-C, Huang C-Y, Lin S-C, Liu C-J, Tsai T-H, et al. Positive correlations of Oct-4 and Nanog in oral cancer stem-like cells and high-grade oral squamous cell carcinoma. Clin Cancer Res. 2008;14:4085-95.
44. Ye F, Zhou C, Cheng Q, Shen J, Chen H. Stem-cell-abundant proteins Nanog, Nucleostemin and Musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer. 2008;18:108-12.
45. Gu T-T, Liu S-Y, Zheng P-S. Cytoplasmic NANOG-positive stromal cells promote human cervical cancer progression. Am J Pathol. 2012;181:652-61.
46. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, et al. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature. 1990;346:240-4.
47. Chew J-L, Loh Y-H, Zhang W, Chen X, Tam W-L, Yeap L-S, et al. Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol. 2005;25:6031-46.
48. Ji J, Zheng PS. Expression of Sox2 in human cervical carcinogenesis. Hum Pathol. 2010;41:1438-47.
49. Li Y, McClintick J, Zhong L, Edenberg HJ, Yoder MC, Chan RJ. Murine embryonic stem cell differentiation is promoted by SOCS-3 and inhibited by the zinc finger transcription factor Klf4. Blood. 2005;105:635-7.
50. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-76.
51. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, et al. Induction of Klf4 in basal keratinocytes blocks the proliferation- differentiation switch and initiates squamous epithelial dysplasia. Oncogene. 2005;24:1491-500.
52. Tai S-K, Yang M-H, Chang S-Y, Chang Y-C, Li W-Y, Tsai T-L, et al. Persistent Kruppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. Cancer Sci. 2011;102:895-902.
53. Dang DT, Chen X, Feng J, Torbenson M, Dang LH, Yang VW. Overexpression of Krüppel-like factor 4 in the human colon cancer cell line RKO leads to reduced tumorigenecity. Oncogene. 2003;22:3424-30.
54. Yang Y, Goldstein BG, Chao H-H, Katz J. Klf4 and Klf5 regulate proliferation, apoptosis and invasion in esophageal cancer cells. Cancer Biol Ther. 2005;4:1216-21.
55. Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC, et al. Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res. 2005;65:2746-54.
56. Zammarchi F, Morelli M, Menicagli M, Di Cristofano C, Zavaglia K, Paolucci A, et al. Klf4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. Am J Pathol. 2011;178:361-72.
57. Hu W, Hofstetter WL, Li H, Zhou Y, He Y, Pataer A, et al. Putative tumor-suppressive function of Krüppel-like factor 4 in primary lung carcinoma. Clin Cancer Res. 2009;15:5688-95.
58. Yang WT, Zheng PS. Krüppel-like factor 4 functions as a tumor suppressor in cervical carcinoma. Cancer. 2012;118:3691-702.
59. Yang J, Chai L, Liu F, Fink LM, Lin P, Silberstein LE, et al. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells. Proc Natl Acad Sci. 2007;104:10494-9.
60. Alkema M, Wiegant J, Raap AK, Bems A, van Lohuizen M. Characterization and chromosomal localization of the human proto-oncogene BMI-1. Hum Mol Genet. 1993;2:1597-603.
61. Tong Y-Q, Liu B, Zheng H-Y, He Y-J, Gu J, Li F, et al. BMI-1 autoantibody as a new potential biomarker for cervical carcinoma. PLoS One. 2011;6:e27804.
62. Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J, et al. Prognostic value of bBi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol. 2008;134:1037-42.
63. Tong Y-Q, Liu B, Huang J, Liu Y, Guo F-J, Zhou G-H, et al. BMI-1 autoantibody in serum as a new potential biomarker of nasopharyngeal carcinoma. Cancer Biol Ther. 2008;7:340-4.
64. Silva J, García V, García JM, Peña C, Domínguez G, Díaz R, et al. Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients. Breast Cancer Res. 2007;9:R55.
65. Yu J, Yu J, Rhodes DR, Tomlins SA, Cao X, Chen G, et al. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res. 2007;67:10657-63.
66. Yong-Qing T, Bei L, Hong-Yun Z, Yu-Juan H, Jian G, Feng L, et al. Overexpression of BMI-1 is associated with poor prognosis in cervical cancer. Asia-Pac J Clin Oncol. 2012;8:e55-62.
67. Xin Z, Chuan-Xin W, Cheng-bao Z, Jian Z, Shi-feng K, Lu-tao D, et al. Overexpression of Bmi-1 in uterine cervical cancer: correlation with clinicopathology and prognosis. Int J Gynecol Cancer. 2010;20:1597-603.
68. Okuda A, Fukushima A, Nishimoto M, Orimo A, Yamagishi T, Nabeshima Y, et al. UTF1, a novel transcriptional coactivator expressed in pluripotent embryonic stem cells and extra-embryonic cells. EMBO J. 1998;17:2019-32.
69. Niwa H. Molecular mechanism to maintain stem cell renewal of ES cells. Cell Struct Funct. 2001;26:137-48.
70. Wang P, Li J, Allan RW, Guo CC, Peng Y, Cao D. Expression of UTF1 in primary and metastatic testicular germ cell tumors. Am J Clin Pathol. 2010;134:604-12.
71. Guenin S, Mouallif M, Deplus R, Lampe X, Krusy N, Calonne E, et al. Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis. PLoS One. 2012;7:e42704.
72. Wu X-L, Zheng P-S. Undifferentiated embryonic cell transcription factor-1 (UTF1) inhibits the growth of cervical cancer cells by transactivating p27Kip1. Carcinogenesis. 2013;34:1660-8.
73. Pepe AE, Xiao Q, Zampetaki A, Zhang Z, Kobayashi A, Hu Y, et al. Crucial role of nrf3 in smooth muscle cell differentiation from stem cells. Circ Res. 2005;106:870-9.
74. Rhee DK, Park SH, Jang YK. Molecular signatures associated with transformation and progression to breast cancer in the isogenic MCF10 model. Genomics. 2008;92:419-28.
75. Almstrup K, Leffers H, Lothe RA, Skakkebaek NE, Sonne SB, Nielsen JE, et al. Improved gene expression signature of testicular carcinoma in situ. Int J Androl. 2007;30:292-303.
76. Perez-Plasencia C, Vazquez-Ortiz G, Lopez-Romero R, Piña-Sanchez P, Moreno J, Salcedo M. Genome wide expression analysis in HPV16 cervical cancer: identification of altered metabolic pathways. Infect Agent Cancer. 2007;2:16-26.
77. Darnell JE. Stats and gene regulation. Science. 1997;277:1630-5.
78. Schaefer TS, Sanders LK, Nathans D. Cooperative transcriptional activity of Jun and Stat3 beta, a short form of Stat3. Proc Natl Acad Sci U S A. 1995;92:9097-101.
79. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415-21.
80. Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, Levy DE, et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol. 2004;24:407-19.
81. Raz R, Lee CK, Cannizzaro LA, d'Eustachio P, Levy DE. Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci U S A. 1999;96:2846-51.
82. Niwa H, Burdon T, Chambers I, Smith A. Self-renewal of pluripotent embryonic stem cells is mediated via activation of stat3. Genes Dev. 1998;12:2048-60.
83. Matsuda T, Nakamura T, Nakao K, Arai T, Katsuki M, Heike T, et al. STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. EMBO J. 1999;18:4261-9.
84. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000;79:67-73.
85. Bowman T, Garcia R, Turkson J, Jove R. Stats in oncogenesis. Oncogene. 2000;19:2474-88.
86. Sobti RC, Singh N, Hussain S, Suri V, Bharti AC, Das BC. Overexpression of STAT3 in HPV-mediated cervical cancer in a north Indian population. Mol Cell Biochem. 2009;330:193-9.
87. Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, et al. Stat3 activation in human endometrial and cervical cancers. Br J Cancer. 2007;96:591-9.
88. Shukla S, Shishodia G, Mahata S, Hedau S, Pandey A, Bhambhani S, et al. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol Cancer. 2010;9:282-301.
89. Denslow SA, Wade PA. The human Mi-2/NuRD complex and gene regulation. Oncogene. 2007;26:5433-8.
90. Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal. 2007;5:E010.
91. Liang J, Wan M, Zhang Y, Gu P, Xin H, Jung SY, et al. Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. Nat Cell Biol. 2008;10:731-9.
92. Mahoney MG, Simpson A, Jost M, Noe M, Kari C, Pepe D, et al. Metastasis-associated protein (MTA) 1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene. 2002;21:2161-70.
93. Jang K-S, Paik SS, Chung H, Oh Y-H, Kong G. MTA1 overexpression correlates significantly with tumor grade and angiogenesis in human breast cancers. Cancer Sci. 2006;97:374-9.
94. Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M, et al. Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer. 2004;110:362-7.
95. Yi S, Guangqi H, Guoli H. The association of the expression of MTA1, nm23H1 with the invasion, metastasis of ovarian carcinoma. Chin Med Sci J. 2003;18:87-92.
96. Han XY, Qian HL, Yang JJ, Zhang XY, Fu M, Liang X, et al. Relationship between MTA1 expression and invasive and metastatic ability of cervical cancer cell. Zhonghua Fu Chan Ke Za Zhi. 2011;46:678-83.
97. Choi JK, Jang SK, Lee DH, Kim KH, Na YJ, Choi KU, et al. Analysis of mta1 gene expression for uterine cervical cancer by cDNA microarray and tissue array. Korean J Obstet Gynecol. 2005;48:2607-17.
98. Kappes F, Burger K, Baack M, Fackelmayer FO, Gruss C. Subcellular localization of the human proto-oncogene protein DEK. J Biol Chem. 2001;276:26317-23.
99. Wu Q, Li Z, Lin H, Han L, Liu S, Lin Z. DEK overexpression in uterine cervical cancers. Pathol Int. 2008;58:378-82.
100. Wise-Draper TM, Allen HV, Thobe MN, Jones EE, Habash KB, Munger K, et al. The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7. J Virol. 2005;79:14309-17.
101. Jung J, Mysliwiec MR, Lee Y. Roles of jumonji in mouse embryonic development. Dev Dyn. 2005;232:21-32.
102. Berge-Lefranc JL, Jay P, Massacrier A, Cau P, Mattei MG, Bauer S, et al. Characterization of the human jumonji gene. Hum Mol Genet. 1996;5:1637-41.
103. Takeuchi T, Watanabe Y, Takano-Shimizu T, Kondo S. Roles of jumonji and jumonji family genes in chromatin regulation and development. Dev Dyn. 2006;235:2449-59.
104. Pedersen MT, Helin K. Histone demethylases in development and disease. Trends Cell Biol. 2010;20:662-71.
105. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7:715-27.
106. Toyoda M, Shirato H, Nakajima K, Kojima M, Takahashi M, Kubota M, et al. Jumonji downregulates cardiac cell proliferation by repressing cyclin D1 expression. Dev Cell. 2003;5:85-97.
107. Kitajima K, Kojima M, Kondo S, Takeuchi T. A role of jumonji gene in proliferation but not differentiation of megakaryocyte lineage cells. Exp Hematol. 2001;29:507-14.
108. Toyoda M, Kojima M, Takeuchi T. Jumonji is a nuclear protein that participates in the negative regulation of cell growth. Biochem Biophys Res Commun. 2000;274:332-6.
109. Takahashi M, Kojima M, Nakajima K, Suzuki-Migishima R, Takeuchi T. Functions of a jumonji-cyclin D1 pathway in the coordination of cell cycle exit and migration during neurogenesis in the mouse hindbrain. Dev Biol. 2007;303:549-60.
110. Takeuchi T, Kojima M, Nakajima K, Kondo S. Jumonji gene is essential for the neurulation and cardiac development of mouse embryos with a C3H/He background. Mech Dev. 1999;86:29-38.
111. Anzai H, Kamiya A, Shirato H, Takeuchi T, Miyajima A. Impaired differentiation of fetal hepatocytes in homozygous jumonji mice. Mech Dev. 2003;120:791-800.
112. Kim J, Chu J, Shen X, Wang J, Orkin SH. An extended transcriptional network for pluripotency of embryonic stem cells. Cell. 2008;132:1049-61.
113. Zhou Q, Chipperfield H, Melton DA, Wong WH. A gene regulatory network in mouse embryonic stem cells. Proc Natl Acad Sci U S A. 2007;104:16438-43.
114. Sun Y, Li H, Liu Y, Mattson MP, Rao MS, Zhan M. Evolutionarily conserved transcriptional co-expression guiding embryonic stem cell differentiation. PLoS One. 2008;3:e3406.
115. Landeira D, Sauer S, Poot R, Dvorkina M, Mazzarella L, Jorgensen HF, et al. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA polymerase II to developmental regulators. Nat Cell Biol. 2010;12:618-24.
116. Pasini D, Cloos PAC, Walfridsson J, Olsson L, Bukowski JP, Johansen JV, et al. Jarid2 regulates binding of the polycomb repressive complex 2 to target genes in ES cells. Nature. 2010;464:306-10.
117. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev. 2010;24:368.
118. Kim T, Chen J, Sadoshima J, Lee Y. Jumonji represses atrial natriuretic factor gene expression by inhibiting transcriptional activities of cardiac transcription factors. Mol Cell Biol. 2004;24:10151-60.
119. Jung J, Kim T, Lyons GE, Kim HRC, Lee Y. Jumonji regulates cardiomyocyte proliferation via interaction with retinoblastoma protein. J Biol Chem. 2005;280:30916-23.
120. Kim T-g, Jung J, Mysliwiec MR, Kang S, Lee Y. Jumonji represses alpha-cardiac myosin heavy chain expression via inhibiting MEF2 activity. Biochem Biophys Res Commun. 2005;329:544-53.
121. Mysliwiec MR, Kim T, Lee Y. Characterization of zinc finger protein 496 that interacts with Jumonji/Jarid2. FEBS Lett. 2007;581:2633-40.
122. Gariglio M, Azzimonti B, Pagano M, Palestro G, de Andrea M, Valente G, et al. Immunohistochemical expression analysis of the human interferon-inducible gene IFI16, a member of the HIN200 family, not restricted to hematopoietic cells. J Interf Cytokine Res. 2002;22:815-21.
123. Wei W, Clarke CJP, Somers GR, Cresswell KS, Loveland KA, Trapani JA, et al. Expression of IFI 16 in epithelial cells and lymphoid tissues. Histochem Cell Biol. 2003;119:45-54.
124. Raffaella R, Gioia D, De Andrea M, Cappello P, Giovarelli M, Marconi P, et al. The interferon-inducible IFI16 gene inhibits tube morphogenesis and proliferation of primary, but not HPV16 E6/E7-immortalized human endothelial cells. Exp Cell Res. 2004;293:331-45.
125. Azzimonti B, Pagano M, Mondini M, De Andrea M, Valente G, Monga G, et al. Altered patterns of the interferon-inducible gene IFI16 expression in head and neck squamous cell carcinoma: immunohistochemical study including correlation with retinoblastoma protein, human papillomavirus infection and proliferation index. Histopathology. 2004;45:560-72.
126. Dawson MJ, Elwood NJ, Johnstone RW, Trapani JA. The IFN-inducible nucleoprotein IFI 16 is expressed in cells of the monocyte lineage, but is rapidly and markedly down-regulated in other myeloid precursor populations. J Leukoc Biol. 1998;64:546-54.
127. Imadome K, Iwakawa M, Nakawatari M, Fujita H, Kato S, Ohno T, et al. Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther. 2010;10:1019-26.
128. Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, et al. ETV1 is a lineage-specific survival factor in gist and cooperates with KIT in oncogenesis. Nature. 2010;467:849-53.
129. Zong Y, Xin L, Goldstein AS, Lawson DA, Teitell MA, Witte ON. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A. 2009;106:12465-70.
130. Li P, Maines-Bandiera S, Kuo W-L, Guan Y, Sun Y, Hills M, et al. Multiple roles of the candidate oncogene ZNF217 in ovarian epithelial neoplastic progression. Int J Cancer. 2007;120:1863-73.
131. Krig SR, Miller JK, Frietze S, Beckett LA, Neve RM, Farnham PJ, et al. ZNF217, a candidate breast cancer oncogene amplified at 20q13, regulates expression of the ErbB3 receptor tyrosine kinase in breast cancer cells. Oncogene. 2010;29:5500-10.
132. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P. The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells. Cancer Res. 2001;61:1250-4.
133. Quinlan KGR, Verger A, Yaswen P, Crossley M. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Biochim Biophys Acta. 2007;1775:333-40.
134. Krig SR, Jin VX, Bieda MC, O'Geen H, Yaswen P, Green R, et al. Identification of genes directly regulated by the oncogene ZNF217 using chromatin immunoprecipitation (ChIP)-chip assays. J Biol Chem. 2007;282:9703-12.
135. Zhu X, Lv J, Yu L, Zhu X, Wu J, Zou S, et al. Proteomic identification of differentially-expressed proteins in squamous cervical cancer. Gynecol Oncol. 2009;112:248-56.
136. López J, Poitevin A, Mendoza-Martínez V, Pérez-Plasencia C, García-Carrancá A. Cancer-initiating cells derived from established cervical cell lines exhibit stem-cell markers and increased radioresistance. BMC Cancer. 2012;12:48.
137. Ouhtit A, Abd Elmageed ZY, Abdraboh ME, Lioe TF, Raj MHG. In vivo evidence for the role of CD44s in promoting breast cancer metastasis to the liver. Am J Pathol. 2007;171:2033-9.
138. Chute JP. Stem cell homing. Curr Opin Hematol. 2006;13:399-406.
139. Qian H, Georges-Labouesse E, Nyström A, Domogatskaya A, Tryggvason K, Jacobsen SEW, et al. Distinct roles of integrins alpha6 and alpha4 in homing of fetal liver hematopoietic stem and progenitor cells. Blood. 2007;110:2399-407.
140. Yao T, Chen Q, Zhang B, Zhou H, Lin Z. The expression of ALDH1 in cervical carcinoma. Med Sci Monit. 2011;17:HY21-6.
141. Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007;67:10538-45.
142. Jeong Seo E, Jung Kim H, Jae Lee C, Tae Kang H, Seong Hwang E. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells. Gynecol Oncol. 2004;94:40-7.
143. Wong C-W, Hou P-S, Tseng S-F, Chien C-L, Wu K-J, Chen H-F, et al. Krüppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. Stem Cells. 2010;28:1510-7.
144. Luczak MW, Roszak A, Pawlik P, Kedzia H, Kedzia W, Malkowska-Walczak B, et al. Transcriptional analysis of CXCR4, DNMT3A, DNMT3B and DNMT1 gene expression in primary advanced uterine cervical carcinoma. Int J Oncol. 2012;40:860-6.
145. Hata K, Okano M, Lei H, Li E. Dnmt3l cooperates with the Dnmt3 family of de novo DNA methyltransferases to establish maternal imprints in mice. Development. 2002;129:1983-93.
146. Meyer N, Penn LZ. Reflecting on 25 years with myc. Nat Rev Cancer. 2008;8:976-90.
147. Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41:843-8.
148. Qiu C, Ma Y, Wang J, Peng S, Huang Y. Lin28-mediated post-transcriptional regulation of Oct4 expression in human embryonic stem cells. Nucleic Acids Res. 2010;38:1240-8.
149. Ertoy D, Ayhan A, Saraç E, Karaagaoglu E, Yasui W, Tahara E, et al. Clinicopathological implication of cripto expression in early stage invasive cervical carcinomas. Eur J Cancer. 2000;36:1002-7.
150. Gray PC, Shani G, Aung K, Kelber J, Vale W. Cripto binds transforming growth factor β (TGF-β) and inhibits TGF-β signaling. Mol Cell Biol. 2006;26:9268-78.
151. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-84.
152. Blagosklonny MV. Why therapeutic response may not prolong the life of a cancer patient: selection for oncogenic resistance. Cell Cycle. 2005;4:1693-8.
153. Frosina G. DNA repair in normal and cancer stem cells, with special reference to the central nervous system. Curr Med Chem. 2009;16:854-66.
154. Wang Y. Effects of salinomycin on cancer stem cell in human lung adenocarcinoma a549 cells. Med Chem. 2011;7:106-11.
155. Kakarala M, Brenner D, Korkaya H, Cheng C, Tazi K, Ginestier C, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat. 2011;122:777-85.
156. Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, et al. Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 2010;70:5004-13.
157. So JY, Lee HJ, Smolarek AK, Paul S, Wang C-X, Maehr H, et al. A novel gemini vitamin D analog represses the expression of a stem cell marker cd44 in breast cancer. Mol Pharmacol. 2010;79:360-7.
158. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010;70:9494-504.
159. Wang L, Guo H, Yang L, Dong L, Lin C, Zhang J, et al. Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-κB activity and apoptosis induction. Mol Cell Biochem. 2013;379:7-18.
160. Liao T, Kaufmann AM, Qian X, Sangvatanakul V, Chen C, Kube T, et al. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol. 2013;139:159-70.
161. Gu W, Yeo E, McMillan N, Yu C. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther. 2011;18:897-905.
162. Cai N, Wang Y-D, Zheng P-S. The microrna-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target akt1. RNA. 2013;19:85-95.